Syngene International · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
U.S. biotech VC funding normalization may take 1-3 more quarters to work through the system before Discovery services growth recovers. Management acknowledged uncertainty on exact timing of recovery.
The Zoetis project was fully operational in Q4 FY23, creating a tough year-on-year comparison for Q4 FY24. Analyst Shaleen Kumar projected potential negative to low single-digit YoY growth for Q4, which management did not explicitly refute.
Operating EBITDA margin declined 200 bps YoY to 27% as fixed costs in Discovery services remain while revenue growth slows. Margin dilution from Stelis facility pre-operative costs will be fully reflected when the plant goes live.
CFO explicitly flagged that lower cash balances following the Stelis acquisition payment will result in reduced interest income, impacting PAT relative to prior periods despite strong underlying business performance.
